SPAST and hereditary spastic paraplegia: miR-33a has been identified as a new target for the treatment of HSP caused by mutations in the spastin gene (Nakazeki et al., 2019), and miR-96 and miR-182 are also involved in the post-transcriptional regulation of spastin protein levels (Henson et al., 2012).